Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

261 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Complement, a target for therapy in inflammatory and degenerative diseases.
Morgan BP, Harris CL. Morgan BP, et al. Among authors: harris cl. Nat Rev Drug Discov. 2015 Dec;14(12):857-77. doi: 10.1038/nrd4657. Epub 2015 Oct 23. Nat Rev Drug Discov. 2015. PMID: 26493766 Free PMC article. Review.
Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
Harris CL, Morgan BP. Harris CL, et al. Immunology. 1995 Oct;86(2):311-8. Immunology. 1995. PMID: 7490134 Free PMC article.
Functional assays for complement regulators.
Harris CL. Harris CL. Methods Mol Biol. 2000;150:83-101. doi: 10.1385/1-59259-056-X:83. Methods Mol Biol. 2000. PMID: 10857104 No abstract available.
Therapeutic uses of recombinant complement receptors.
Morgan BP, Rushmere NK, Harris CL. Morgan BP, et al. Among authors: harris cl. Biochem Soc Trans. 1998 Feb;26(1):49-54. doi: 10.1042/bst0260049. Biochem Soc Trans. 1998. PMID: 10909756 Review. No abstract available.
Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
Harris CL, Spiller OB, Morgan BP. Harris CL, et al. Immunology. 2000 Aug;100(4):462-70. doi: 10.1046/j.1365-2567.2000.00066.x. Immunology. 2000. PMID: 10929073 Free PMC article.
Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.
Fraser DA, Harris CL, Smith RA, Morgan BP. Fraser DA, et al. Among authors: harris cl. Protein Sci. 2002 Oct;11(10):2512-21. doi: 10.1110/ps.0212402. Protein Sci. 2002. PMID: 12237472 Free PMC article.
Tailoring anti-complement therapeutics.
Harris CL, Fraser DA, Morgan BP. Harris CL, et al. Biochem Soc Trans. 2002 Nov;30(Pt 6):1019-26. doi: 10.1042/bst0301019. Biochem Soc Trans. 2002. PMID: 12440965 Review.
Generation of anti-complement "prodrugs": cleavable reagents for specific delivery of complement regulators to disease sites.
Harris CL, Hughes CE, Williams AS, Goodfellow I, Evans DJ, Caterson B, Morgan BP. Harris CL, et al. J Biol Chem. 2003 Sep 19;278(38):36068-76. doi: 10.1074/jbc.M306351200. Epub 2003 Jul 3. J Biol Chem. 2003. PMID: 12842884
Complement therapeutics; history and current progress.
Morgan BP, Harris CL. Morgan BP, et al. Among authors: harris cl. Mol Immunol. 2003 Sep;40(2-4):159-70. doi: 10.1016/s0161-5890(03)00111-1. Mol Immunol. 2003. PMID: 12914822 Review.
Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).
Harris CL, Abbott RJ, Smith RA, Morgan BP, Lea SM. Harris CL, et al. J Biol Chem. 2005 Jan 28;280(4):2569-78. doi: 10.1074/jbc.M410179200. Epub 2004 Nov 9. J Biol Chem. 2005. PMID: 15536079
261 results
Jump to page
Feedback